December 30, 2020 - The court granted the defendants' motion to dismiss. The plaintiffs were not given leave to amend the complaint.

September 17, 2020 - A motion to dismiss the second consolidated complaint was filed.

August 10, 2020 - A second consolidated complaint was filed.

July 13, 2020 - The court granted the defendants' motion to dismiss. The plaintiffs were given leave to amend the complaint.

August 2, 2019 - A motion to dismiss the consolidated complaint was filed.

May 15, 2019 - A consolidated complaint was filed.

October 30, 2018 - An investor in shares of Nektar Therapeutics (NASDAQ: NKTR) filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by Nektar Therapeutics in connection with certain allegedly false and misleading statements made between November 11, 2017, and October 2, 2018.

San Francisco, CA based Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. NKTR-214, is the Company’s lead immune-oncology (“I-O”) candidate, is a biologic with biased signaling through one of the IL-2 receptor subunits (CD 122) that can stimulate proliferation and growth of tumor-killing immune cells in the tumor microenvironment and increase expression of PD-1 on these immune cells.

On October 1, 2018, Plainview LLC published a report raising questions about Nektar Therapeutics’ claims concerning its clinical stage drug, NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer, and its ability to effectively treat cancer.

Shares of Nektar Therapeutics (NASDAQ: NKTR) declined to as low as $51.74 per share on October 4, 2018.

According to the complaint the plaintiff alleges on behalf of purchasers of Nektar Therapeutics (NASDAQ: NKTR) common shares between November 11, 2017, and October 2, 2018, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between November 11, 2017, and October 2, 2018, the Defendants made false and/or misleading statements and/or failed to disclose that prior studies which attempted to pegylate IL-2 failed, that NKTR-214’s extended half-life was unlikely to result in efficacy and created additional high-dosing safety concerns, that NKTR-214 was less effective than IL-2 alone, that the combination of NKTR-214 with nivolumab has not yet demonstrated significant positive results, and that as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.